8-K: Stoke Therapeutics and Biogen Collaborate on Zorevunersen for Dravet Syndrome Treatment

Stoke Therapeutics and Biogen have entered into a licensing and collaboration agreement to develop and commercialize zorevunersen for Dravet syndrome, with Biogen gaining exclusive rights outside of the United States, Canada, and Mexico.

Summary

• Stoke Therapeutics and Biogen have entered into a License and Collaboration Agreement for the development and commercialization of zorevunersen (STK-001) for Dravet syndrome.
• Biogen will have exclusive rights to commercialize zorevunersen outside the United States, Canada, and Mexico.
• Stoke will receive an upfront payment of $165 million from Biogen.
• The companies will share external development costs, with Stoke paying 70 percent.
• Stoke is eligible to receive up to $385 million in milestone payments.
• Stoke will also receive tiered royalties on future net sales by Biogen, ranging from low double digits to high teens.
• The agreement includes a joint steering committee to oversee development and commercialization.
• The agreement remains in effect until the expiration of the royalty term on a country-by-country and product-by-product basis.
• Stoke expects its cash, cash equivalents, and marketable securities, along with the upfront payment and other eligible cash flows from Biogen, to fund operations through mid-2028.
• Stoke plans to initiate the Phase 3 Emperor study in the second quarter of 2025, with data anticipated in the second half of 2027.

Sentiment

Score: 8

Explanation: The document presents a positive outlook due to the collaboration agreement, significant upfront payment, potential milestone payments, and extended cash runway for Stoke Therapeutics. The partnership with Biogen, a well-established company, further strengthens the positive sentiment.

Positives

• The collaboration provides Stoke with a significant upfront payment of $165 million.
• Stoke has the potential to receive up to $385 million in milestone payments.
• Stoke will receive tiered royalties on future net sales by Biogen.
• The collaboration extends Stoke's cash runway through mid-2028.
• Stoke retains commercial rights in the United States, Canada, and Mexico.
• Biogen's expertise in commercializing rare disease medicines could accelerate zorevunersen's global reach.

Negatives

• Stoke will pay 70% of external development costs.
• The agreement is subject to standard royalty reductions.
• The success of zorevunersen is dependent on clinical trial outcomes and regulatory approvals.

Risks

• The success of the collaboration depends on the ability of both companies to effectively develop and commercialize zorevunersen.
• Clinical trial results may not be positive, and regulatory approvals may not be granted.
• The collaboration could be terminated under certain circumstances, potentially impacting Stoke's financial position.
• Global business, political, and macroeconomic conditions could impact the collaboration and development efforts.
• Intellectual property protection is crucial for the success of zorevunersen.

Future Outlook

Stoke expects the collaboration with Biogen, along with its existing cash reserves, to fund operations through mid-2028, and anticipates initiating the Phase 3 Emperor study in the second quarter of 2025, with data expected in the second half of 2027.

Management Comments

• Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics, stated that the collaboration aims to lead the treatment of Dravet syndrome into a new era by delivering zorevunersen to all patients who could benefit.
• Priya Singhal, M.D., M.P.H., Head of Development at Biogen, said that the collaboration broadens Biogen's late-stage pipeline and allows them to leverage their rare disease product commercialization expertise and global footprint.

Industry Context

This collaboration reflects a growing trend in the pharmaceutical industry towards partnerships to develop and commercialize treatments for rare diseases. Biogen's expertise in neurology and rare genetic diseases complements Stoke's focus on RNA-based medicines, potentially accelerating the development and commercialization of zorevunersen.

Comparison to Industry Standards

• The upfront payment of $165 million is within the typical range for licensing agreements of this nature, especially considering the Phase 3 readiness of zorevunersen.
• The potential milestone payments of up to $385 million are also competitive with industry standards for similar deals.
• Companies like Sarepta Therapeutics and Ionis Pharmaceuticals have also pursued similar antisense oligonucleotide therapies for rare genetic diseases, providing a benchmark for potential success.
• Biogen's existing portfolio of rare disease treatments, such as SPINRAZA for spinal muscular atrophy, demonstrates their capability to successfully commercialize specialized therapies.

Stakeholder Impact

• Shareholders of Stoke Therapeutics are likely to react positively to the news of the collaboration and the associated financial benefits.
• Patients with Dravet syndrome and their families may benefit from the potential development of a new disease-modifying treatment.
• Employees of Stoke Therapeutics may experience increased job security and opportunities due to the collaboration.
• Biogen's stakeholders may benefit from the expansion of their rare disease pipeline and potential revenue from zorevunersen.

Next Steps

• Stoke and Biogen will establish a joint steering committee to oversee the development and commercialization of zorevunersen.
• Stoke plans to initiate the Phase 3 Emperor study in the second quarter of 2025.
• The companies will work towards obtaining regulatory approvals for zorevunersen in various territories.

Key Dates